GlassScriptPhysician profile
Tina E Griffin
NPI 1962700385
$378.35
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.92 · 2022: $332.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $96.22 | 2022 | |
| Merck Sharp & Dohme LLC | $76.22 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $50.92 | 2022 | |
| Celgene Corporation | $29.55 | 2022 | |
| Pfizer INC. | $27.41 | 2022 | |
| Eisai INC. | $21.65 | 2022 | |
| Eusa Pharma (US) LLC | $17.58 | 2021 | |
| Daiichi Sankyo INC. | $16.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.80 | 2021 | |
| Foundation Medicine, INC. | $14.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.